More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.46B
EPS
-3.52
P/E ratio
--
Price to sales
83.92
Dividend yield
--
Beta
1.146776
Previous close
$21.88
Today's open
$21.76
Day's range
$20.52 - $21.76
52 week range
$8.73 - $51.72
show more
CEO
Matthew Kapusta
Employees
221
Headquarters
Amsterdam,
Exchange
Nasdaq Global Select
Shares outstanding
70138860
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
uniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore
The FDA reversed its support for natural-history controls, demanded a sham-controlled trial, then reversed course again, delaying progress for months while Huntington's patients continued suffering irreversible decline. The latest Enroll-HD comparator is biased toward much slower-progressing Huntington's disease patients, as faster progressors are dropping out of the comparator over time, potentially materially understating AMT-130's treatment benefit. High-dose AMT-130 showed 80% slowing on cUHDRS at three years and 61% on TFC at four years; the four-year primary test missed significance.
Seeking Alpha • Nov 14, 2026

uniQure CEO Defends Huntington's Therapy Data, Sees Opportunity Ahead of FDA Decision
uniQure NASDAQ: QURE Chief Executive Matt Kapusta said investors are focused on regulatory risk surrounding its experimental Huntington's disease therapy, AMT-130, but may be underestimating the need for treatment and the potential commercial opportunity.
MarketBeat • Nov 13, 2026

uniQure Prepares for Potential FDA Panel on Huntington's Gene Therapy After Priority Review Nod
uniQure NASDAQ: QURE is preparing for a potential U.S. advisory committee meeting on AMT-130, its experimental gene therapy for Huntington's disease, after regulators accepted its biologics license application for priority review, CEO Matt Kapusta said.
MarketBeat • Nov 13, 2026

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.
Zacks Investment Research • Nov 13, 2026

uniQure Q3 Earnings Call Highlights
uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a target action date of May 1, 2027. The U.K. Medicines and Healthcare products Regulatory Agency has also validated the company's Marketing Authorization Application, according to management.
MarketBeat • Nov 4, 2026

uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~
GlobeNewsWire • Nov 4, 2026

uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.
Zacks Investment Research • Nov 4, 2026

uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade)
uniQure's stock has come under significant pressure again after the company reported mixed 4-year AMT-130 data. While measurement noise and control bias likely explain much of the disappointing results, there is now greater uncertainty around durability. I believe that uniQure's data is strong enough to support accelerated approval despite this, though.
Seeking Alpha • Nov 4, 2026

Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA
The FDA said Monday it will make an approval decision on Uniqure's Huntington's gene therapy by May 1. But Uniqure stock fell.
Investors Business Daily • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell uniQure N.V. commission-free¹. Build wealth for the long term using automated trading and transfers.